Lymphodepletion improves efficacy of CAR T cells in HL

Crowd exiting a session at the 2018 ASH Annual Meeting
© ASH/Rodney White 2018
A phase 1 study suggests lymphodepletion can improve the efficacy of CD30-directed chimeric antigen receptor (CAR) T-cell therapy in patients with Hodgkin lymphoma (HL). Researchers observed improved responses in HL patients treated with fludarabine and cyclophosphamide prior to CD30.CAR T-cell therapy. This lymphodepleting regimen was also associated with increased toxicity, compared to no lymphodepletion. However, researchers consider the regimen safe. [Read Article]

Fludarabine deemed important for CD30.CAR T-cell therapy

Attendees at ASH 2018
Photo courtesy of ASH
Fludarabine is “very important” for lymphodepletion prior to CD30-directed chimeric antigen receptor (CAR) T-cell therapy, according to a presentation at the 2018 ASH Annual Meeting. A phase 1/2 study showed that bendamustine alone was not sufficient as lymphodepletion. However, adding fludarabine to bendamustine could enhance responses to CD30.CAR T-cell therapy and improve progression-free survival (PFS) in patients with Hodgkin or non-Hodgkin lymphoma. [Read Article]

MetS after HSCT linked to CV events, second cancers

Attendees at ASH 2018
Photo courtesy of ASH
Patients who develop metabolic syndrome (MetS) after hematopoietic stem cell transplant (HSCT) have an increased risk of cardiovascular (CV) events and second malignancies, according to research presented at the 2018 ASH Annual Meeting. Researchers found that HSCT recipients had a higher prevalence of MetS than the general population, and the incidence of MetS increased with age. In addition, MetS was a predictor of CV events, and these events were associated with second malignancy. [Read Article]